Thermo Fisher Scientific has showcased innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics during AACC 2022 in Chicago.
"Our latest platform and workflow innovations give clinical laboratories and researchers greater flexibility and assurance as they respond to new and existing diagnostic challenges," said Gianluca Pettiti, executive vice president, Thermo Fisher Scientific. "By minimising hands-on time, reducing time-to-results, and improving analytical performance, we’re enabling the science that shapes the future of diagnostics, as we all work toward improving patient outcomes."
The Applied Biosystems TaqMan-SARS-CoV-2 Mutation Panel enables laboratories to build their own custom panel from a menu of verified real-time PCR assays. This meets the evolving needs of customers and public health agencies seeking to rapidly identify and survey current mutations as well as emerging variants.
To support laboratories as they move beyond COVID testing, Thermo Fisher is evolving its respiratory testing menu and improving automation to accelerate research. The Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit helps laboratories expand their existing COVID-19 testing menu for respiratory samples while maintaining workflow simplicity and without increasing operational costs.
Also featured at AACC was the new Thermo Scientific KingFisher SpeciTRAX Sample Transfer System, which provides researchers in infectious diseases and genetics with an automated sample-handling system, including new features, such as an automated decapper, that relieve the sample processing bottleneck for increased throughput.
Information on all the Thermo Fisher products and solutions exhibited at AACC 2022 is available at thermofisher.com/aacc
